Growth credible, but margin compression and Aquapharm miss signal execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
EBITDA/tonne improvement guidance on track. Aquapharm ₹75 Cr quarterly target formally deferred; no new target given. Volume guidance softened from 'high single-digit' to 'challenging.'
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
YoY growth credible (14% revenue, 20% PAT) and pricing discipline proven. But -52% QoQ PAT collapse, Aquapharm shortfall (₹42 Cr EBITDA vs ₹75 Cr prior), and export pullback signal weakening demand and execution risk. Long-term structural tailwinds (tyre expansion, battery materials) are real but require flawless H2 delivery and margin stabilization.
₹2474.4 Cr
Revenue · +14.4% YoY₹74.1 Cr
Reported PAT · +20.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenue grew 14% YoY
MET₹2,474.4 Cr, +14.4% YoY; flat QoQ reveals weak Q1
Profit after tax grew 20% YoY
MET₹74.1 Cr, +20.2% YoY but -52.1% QoQ; sequential collapse concerning
EBITDA grew 12% YoY to ₹310 Cr
MET₹310 Cr reported; 12% YoY growth claimed; no contradiction
Aquapharm double-digit growth H2 FY27
MISSQ2 EBITDA ₹42 Cr; prior ₹75 Cr quarterly target abandoned, not reiterated
Export volume recovery on track
OVERSTATEDExports -18% QoQ; pulled back deliberately due to margin pressure and customer caution
Earnings quality
What changed since the last call
Aquapharm EBITDA guidance
WithdrawnPrior ₹75 Cr quarterly EBITDA target deferred by new CEO. Q2 delivered ₹42 Cr; H2 now guided as 'double-digit growth' only
Volume growth outlook
DowngradeWas 'high single-digit weighted to H2'; now labeled 'challenging' by management. Export pullback -18% QoQ
EBITDA/tonne guidance
NeutralReaffirmed double-digit improvement vs FY26 avg (₹16,500-17,000/tonne base). Tracking as expected; no change
Pricing posture
UpgradeManagement emphasizing 'pricing discipline and margin focus' over volume chasing. Spot prices expected higher Nov-Dec
The Q&A
Analysts pressed hard on export volume miss, Aquapharm target abandonment, and softened volume guidance. Management held firm on strategy (disciplined margins over volume) but gave limited H2 recovery path detail. Candid on challenges, not evasive.
Inventory destocking — Rohit Sinha, Sundhi Securities
AnsweredCrude fell to $70, customers reduced stock; now at $110. Customers in wait-and-watch; gradual not sharp buildup expected.
Cost program scale — Sailesh Raja, 360 ONE Capital
AnsweredMostly fixed cost (volume-linked). Structural ~₹10-15 Cr. Acceleration via yield and throughput initiatives in coming quarters.
Export volume forecast — Sailesh Raja, 360 ONE Capital
PartialPulled back due to low margins in Southeast Asia. U.S./Europe infrastructure setup will unlock growth next year.
Specialty Carbon Black — Sailesh Raja, 360 ONE Capital
PartialLine 6 commercialized, Mundra Line coming. Feedstock is the constraint. Significant growth expected as sourcing improves.
Aquapharm growth drivers — Aditya Khetan, SMIFS
AnsweredDriven by volume (new products: PBTC, GLDA) plus pricing. HEDP duty impact TBD; working on finalization.
Antidumping duty — Aditya Khetan, SMIFS
PartialProvisional now; finalizing. No specific numbers in forecast yet. Will help both margin and volume.
Raw material sourcing — Aditya Khetan, SMIFS
PartialDiversifying to U.S., Korea, Malaysia, Thailand. Quality and yield must match. Premium 1-2% on Southeast Asia.
Volume growth guidance — Aditya Khetan, SMIFS
AnsweredThat's challenging now. Macro headwinds and customer caution. EBITDA/tonne guidance continues.
Carbon Black spread dynamics — Harsh Motika, SKP Securities
AnsweredSpread ~₹17,500/tonne net EBITDA this quarter. Russia supply tightness and China cost inflation should support H2.
Battery materials timeline — Harsh Motika, SKP Securities
PartialSilicon carbon composite in internal trials. Not graphite yet. Trials progressing Palej, Belgium, Australia sites.
Guidance
FY27 double-digit revenue growth
Medium14.4% YoY Q2 sets pace for 12%+ FY27 if H2 stable. Dependent on inventory normalization and macro
Carbon Black domestic high single-digit; export recovery FY28
LowExport volumes down; recovery now pushed to next year due to tariff, macro uncertainty
Aquapharm FY27 double-digit revenue growth
LowQ2 ₹433 Cr; prior ₹75 Cr quarterly EBITDA target abandoned. H2 growth dependent on new product uptake
EBITDA/tonne: double-digit improvement over FY26 avg (₹16,500-17,000/tonne)
HighReaffirmed on call. Current run-rate ₹17,500/tonne implies ~6% improvement. On track
Operating margin: pricing discipline focus, volume secondary
MediumNPM 3.0% suggests significant tax/interest burden. Margin profile softer than headline growth implies
FY27 capex ~₹300 Cr; Specialty CB Line 6 done, Mundra Line in progress
MediumCoal tar plant finalization ongoing. Depends on supplier contracts (almost finalized)
Risks the call surfaced
Geopolitical & tariff
MediumU.S.-India tariff negotiations ongoing. Russia CBFS supply disruptions impacting global flows. Customers delaying sourcing decisions.
Volume & demand
MediumCustomers maintaining lean inventory due to crude price uncertainty. Volume guidance softer than prior. Export pullback deliberate.
Aquapharm execution
HighAquapharm Q2 EBITDA ₹42 Cr vs prior ₹75 Cr quarterly target (56% miss). Target formally deferred. New CEO analyzing business model.
Margin pressure
MediumShipping, freight, power costs elevated. Crude volatility impacting feedstock costs. Customer caution reducing operating leverage. NPM only 3.0%.
Specialty Carbon Black
MediumSpecialty CB capacity ~75 tonnes. Feedstock availability is a critical bottleneck. Mundra Line expansion at risk if sourcing doesn't improve.
Management
Score 7/10. Candid on headwinds (geopolitical, inventory destocking, freight/power cost inflation). Transparent on Aquapharm challenge and target deferral. Good strategy articulation. Some vagueness on Aquapharm remediation and H2 recovery specifics. Pricing discipline delivered (14% revenue, 20% PAT YoY). Volume management disciplined but demand-driven. Aquapharm execution lagging significantly. Cost program (Alchemy) on track.
1 · Q3-Q4 FY27
Customer inventory normalization; ordering patterns improve on price clarity
2 · H2 FY27
Russian CBFS supply constraints firm pricing; China coal tar price inflation supports spreads
3 · FY28
U.S./Europe warehouse infrastructure yields export volume growth
Long-term structural tailwinds (tyre expansion, battery materials) are real but require flawless H2 delivery and margin stabilization.
Informational and educational content only. Not investment advice.